Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK525762 phase II expansion in NUT midline carcinoma and selected solid tumors
NL-OMON43804Phase 2Not yet recruiting
- Sponsor
- GSK
- Start
- Oct 2015
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of molibresib in NUT carcinoma (NC), small cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC) and 2 more (5 cohorts), sponsored by GSK. Primary endpoints: Adverse events and Overall response rate. Planned start Oct 2015; status: not yet recruiting.
02
Drugs
molibresib
03
Conditions
NUT carcinoma (NC)small cell lung cancer (SCLC)castration-resistant prostate cancer (CRPC)triple-negative breast cancer (TNBC)estrogen receptor-positive breast cancer
Beyond the preview
Go deeper on NL-OMON43804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43804.